Merlo, Daniel, Stankovich, Jim, Darby, David, Butzkueven, Helmut, Van der Walt, Anneke, Bai, Claire, Kalincik, Tomas, Zhu, Chao, Gresle, Melissa, Lechner-Scott, Jeannette, Kilpatrick, Trevor, Barnett, Michael, Taylor, Bruce. Wolters Kluwer Health; 2021. Association between cognitive trajectories and disability progression in patients with relapsing-remitting multiple sclerosis.

Spelman, Tim, Horakova, Dana, Csepany, Tunde, Boz, Cavit, Lechner-Scott, Jeannette, Granella, Franco, Grand'Maison, Francois, van der Walt, Anneke, Zhu, Chao, Butzkueven, Helmut, Ozakbas, Serkan, Alroughani, Raed, Onofrj, Marco, Kalincik, Tomas, Prat, Alexandre, Terzi, Murat, Grammond, Pierre, Patti, Francesco. Elsevier; 2023. Switching to natalizumab or fingolimod in multiple sclerosis: Comparative effectiveness and effect of pre-switch disease activity.

Zhu, Chao, Kalincik, Tomas, Patti, Francesco, Grand'Maison, Francois, Hodgkinson, Suzanne, Grammond, Pierre, Lechner-Scott, Jeannette, Butler, Ernest, Prat, Alexandre, Girard, Marc, Duquette, Pierre, Macdonell, Richard A. L., Horakova, Dana, Weinstock-Guttman, B, Ozakbas, S, Slee, M, Sa, MJ, Van Pesch, V, Barnett, M, Van Wijmeersch, B, Gerlach, O, Prevost, J, Terzi, M, Zhou, Zhen, Boz, C, Laureys, G, Van Hijfte, L, Kermode, AG, Garber, J, Yamout, B, Khoury, SJ, Merlo, D, Monif, M, Jokubaitis, V, Buzzard, Katherine, van der Walt, A, Butzkueven, H, MSBase, SG, Skibina, Olga, Alroughani, Raed, Izquierdo, Guillermo, Eichau, Sara, Kuhle, Jens. American Medical Association (AMA); 2023. Comparison Between Dimethyl Fumarate, Fingolimod, and Ocrelizumab After Natalizumab Cessation.

Zhu, Chao, Zhou, Zhen, Alroughani, Raed, Lechner-Scott, Jeannette, Barnett, Michael, Izquierdo, Guillermo, Prat, Alexandre, Horakova, Dana, Havrdova, Eva Kubala, Macdonell, Richard, Patti, Francesco, Khoury, Samia Joseph, Roos, Izanne, Slee, M, Karabudak, R, Onofrj, M, Van Pesch, V, Prevost, J, Monif, M, Jokubaitis, V, van der Walt, A, Butzkueven, H, Merlo, Daniel, Kalincik, Tomas, Ozakbas, Serkan, Skibina, Olga, Kuhle, Jens, Hodgkinson, Suzanne, Boz, Cavit. BMJ Group; 2022. Comparing switch to ocrelizumab, cladribine or natalizumab after fingolimod treatment cessation in multiple sclerosis.